Efficacy of quabodepistat alone and in combination with delamanid and bedaquiline against Mycobacterium tuberculosis in an NHP model evaluated by [ 18 F] FDG PET/CT and bacterial burden
Antimicrobial Agents and Chemotherapy · 2026
DOI: 10.1128/aac.00280-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von L E Via und 22 weiteren Autor:innen. Beteiligte Einrichtung: Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy, and Infectious Diseases (NIAID), Na…. Hauptthemen laut MEDLINE: Oxazoles, Diarylquinolines, Antitubercular Agents, Mycobacterium tuberculosis. Die Arbeit nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bill & Melinda Gates Foundation, NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Multidrug-resistant tuberculosis (MDR-TB) is challenging. Bedaquiline (B), delamanid (D), and pretomanid (P) are used in combination regimens with other anti-TB drugs for MDR-TB; however, agents with novel mechanisms of action are needed. DprE1 inhibitor quabodepistat (Q) was developed for combination use. In this study, Q alone or in combination with human-equivalent doses of D and/or B was evaluated in a marmoset TB model using in vivo imaging, with terminal bacterial counts from all lung lesions. Marmosets were infected with H37Rv Mycobacterium tuberculosis and allowed to develop the disease for 7 weeks. They were then administered a pre-treatment 18 F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) scan and randomized into seven treatment groups ( n = 5/group). At 2 weeks, the quabodepistat-treated groups showed a significant reduction in lesion volume compared to those without the agent in a post hoc analysis. After 2 months, the animals were euthanized, and the bacterial burden and histology were assessed. Marmosets treated with all agents showed reduced lung disease on PET/CT (>70%) compared to their pre-treatment disease volume. B reduced extrapulmonary bacteria more significantly than Q or D. Cavities and necrotic lesions from DBQ-treated animals had lower bacterial burdens than lesions treated with any of the single-agent or two-agent combinations. In a preliminary comparison, DBQ showed no statistically detectable difference from the standard-of-care regimen isoniazid-rifampicin-pyrazinamide-ethambutol (HRZE). Additionally, the activities of D and P monotherapies were similar in this model. The evaluation of these agents in the marmoset TB model supports further investigation of Q as a component of shorter TB regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy, and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA.
- Tuberculosis Imaging Program, Division of Intramural Research, NIAID, NIH, Bethesda, Maryland, USA.
- Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
- Department of Medical Sciences, Hackensack Meridian School of Medicine, Nutley, New Jersey, USA.
- Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts, USA.
- Department of Biomedical Engineering, Tufts University School of Engineering, Medford, Massachusetts, USA.
ORCID-Profile: L E Via, D M Weiner, M Zimmerman, B B Aldridge, C E Barry
Förderung
- Bill & Melinda Gates Foundation
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
- Bill and Melinda Gates Foundation
- NIH HHS
- National Institutes of Health
Zitieren
APA
Via, L. E., Sarathy, J., Weiner, D. M., Greenstein, T., Zimmerman, M., Abdi, A., Fleegle, J. D., Gomez, F., Kaya, F., Piazza, M. K., Vatthauer, A., Sloan, B. Y., Repoli, K. M., Walker, A. M., Woodcock, M. J., Egbelowo, O., Gausi, K., Boshoff, H. I. M., Liu, Y., …, & Barry, C. E. (2026). Efficacy of quabodepistat alone and in combination with delamanid and bedaquiline against Mycobacterium tuberculosis in an NHP model evaluated by [ 18 F] FDG PET/CT and bacterial burden. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00280-26
Vancouver
Via LE, Sarathy J, Weiner DM, Greenstein T, Zimmerman M, Abdi A, et al. Efficacy of quabodepistat alone and in combination with delamanid and bedaquiline against Mycobacterium tuberculosis in an NHP model evaluated by [ 18 F] FDG PET/CT and bacterial burden. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.00280-26
BibTeX
@article{Via2026,
author = {Via, L E and Sarathy, J and Weiner, D M and Greenstein, T and Zimmerman, M and Abdi, A and Fleegle, J D and Gomez, F and Kaya, F and Piazza, M K and Vatthauer, A and Sloan, B Y and Repoli, K M and Walker, A M and Woodcock, M J and Egbelowo, O and Gausi, K and Boshoff, H I M and Liu, Y and Chadalavada, D and Aldridge, B B and Dartois, V and Barry, C E},
title = {Efficacy of quabodepistat alone and in combination with delamanid and bedaquiline against Mycobacterium tuberculosis in an NHP model evaluated by [ 18 F] FDG PET/CT and bacterial burden},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.00280-26}
}
EUVIMED